A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia

International Journal of Hematology

Volumn 96, Issue 2, 2012, Pages 222-228

  Wang, Shujie ^a   Yang, Renchi ^b   Zou, Ping ^c   Hou, Ming ^d   Wu, Depei ^e   Shen, Zhixiang ^f   Lu, Xijing ^g   Li, Yan ^h   Chen, Xiequn ⁱ   Niu, Ting ^j   Sun, Hui ^k   Yu, Li ^l   Wang, Zhao ^m   Zhang, Yin ⁿ   Chang, Naibai ^o   Zhang, Gaokui ^p   Zhao, Yongqiang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SHANDONG UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^j SICHUAN UNIVERSITY   (China)

^k THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^l CHINESE PLA GENERAL HOSPITAL   (China)

^m CAPITAL MEDICAL UNIVERSITY   (China)

ⁿ HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^o BEIJING HOSPITAL   (China)

^p Beijing DMS Pharma Ltd   (China)

more..

Author keywords

Primary immune thrombocytopenia (ITP); Recombinant human thrombopoietin (rhTPO); Thrombopoietin (TPO)

Indexed keywords

ANTIFIBRINOLYTIC AGENT; DANAZOL; GLUCOCORTICOID; LIVER PROTECTIVE AGENT; RECOMBINANT THROMBOPOIETIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; INJECTION SITE PAIN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; MULTICENTER STUDY; ORAL BLEEDING; PRIMARY IMMUNE RESPONSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; RECOMBINANT PROTEINS; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866998566     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1124-8     Document Type: Article

References (25)

1. Rodeghiero F, Ruggeri M. Chronic immune thrombocytopenic purpura. New agents. Hamostaseologie. 2009;29:76-9.
2. Kuter DJ. Future directions with platelet growth factors. Semin Hematol. 2000;37:41-9.
3. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887-95.
4. Cremer M, Schulze H, Linthorst G, Folman CC, Wehnert S, Strauss G, et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. Ann Hematol. 1999;78:401-7.
5. Hou M, Ji CY, Zhu YY, Xu CG, Zhang MH. Serum thrombopoietin level in patients with thrombocytopenia. Chin J Med. 1999;79:356-7.
6. Liao XM, Deng CQ, Niu T, Meng WT, Zhang J, Wang Y. Study of thrombopoietin and chronic idiopathic thrombocytopenia purpura. Chin J Hematol. 2001;22:473-5.
7. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-8.
8. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-8.
9. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-71.
10. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571-4.
11. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94:365-7.
12. von dem Borne A, Folman C, van den Oudenrijn S, Linthorst G, de Jong S, de Haas M. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev. 2002;16:57-9.
13. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628-38.
14. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395-403.
15. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85-93.
16. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641-8.
17. Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, et al. A multicenter clinical study of rhTPO treatment in chronic refractory idiopathic thrombocytopenia purpura. Chin J Intern Med. 2004;43:608-10.
18. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-8.
19. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599-602.
20. Hua BL, Zhao YQ, Wang SJ, Zhu TN, Zhao YQ. Development of recombinant human thrombopoietin antibodies following multidosing, subcutaneously medication in thrombocytopenic patients. Chin J Thromb Hemostasis. 2005;2:59-61.
21. Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol. 2008;69(Suppl):9-18.
22. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68:901-12.
23. Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109:4607-16.
24. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-47.
25. Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics. 2010;4:139-45.